Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dose, Multicenter Study of Weight-Reducing and Prevention of Weight Regain Effects and Safety in Obese Patients With or Without Comorbidities.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 15 May 2009
Price :
$35
*
At a glance
- Drugs Rimonabant (Primary)
- Indications Obesity
- Focus Registrational; Therapeutic Use
- Acronyms RIO-North America
- Sponsors Sanofi-Synthelabo
- 12 May 2009 Primary endpoint identified as body weight as reported by ClinicalTrials.gov.
- 14 Sep 2006 New trial record.